Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29029215 | 0.98 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| SCHEMBL10569701 | 0.98 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| Hydrochloric Acid SCHEMBL28453921 | 0.96 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| SCHEMBL28711798 | 0.87 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| SCHEMBL1515754 | 0.79 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| SCHEMBL6160196 | 0.78 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A | |
| Ammonia Solution, Strong SCHEMBL27626967 | 0.77 | KDM4E (0.52) | ALDH1A1KDM4ECYP3A4MAPTALOX15 | |
| SCHEMBL17858535 | 0.77 | DYRK1A (0.42) | SLC6A2SLC6A4SLC6A3ALDH1A1RAB9A | |
| SCHEMBL7640862 | 0.76 | KDM4E (0.39) | SLC6A2SLC6A4SLC6A3ALDH1A1KDM4E | |
| SCHEMBL11215459 | 0.75 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3CHRM2SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | K AND K BIOSCIENCE, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| US-20040073039-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | K AND K BIOSCIENCES, INC. | 2004-04-15 | — | — | US | disclosed |
| US-6638954-B2 | Antiepileptic agents; stroke therapy | K AND K BIOSCIENCES, INC. | 2003-10-28 | — | — | US | disclosed |
| US-20020111371-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | K AND K BIOSCIENCES, INC. | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | SIGMAR1, GRM1, GRIN2C | SLC6A2 1494/4885SLC6A4 1569/4885SLC6A3 789/4885 |
| US-20040073039-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | SIGMAR1, GRM1, GRIN2C | SLC6A2 1753/4885SLC6A4 1735/4885SLC6A3 986/4885 |
| US-20020111371-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | SIGMAR1, GRM1, GRIN2C | SLC6A2 1753/4885SLC6A4 1735/4885SLC6A3 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.